Pozahipotensyjne korzyści ze stosowania kandesartanu ze szczególnym uwzględnieniem populacji kobiet Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
cze 30, 2017
Słowa kluczowe:
kandesartan, sartany, antagoniści receptora dla angiotensyny II, nadciśnienie tętnicze, niewydolność serca, choroby zapalne mózgu
##plugins.themes.bootstrap3.article.main##
Abstrakt
Kandesartan to selektywny antagonista receptora AT1 dla angiotensyny II szeroko stosowany w chorobach układu sercowo-naczyniowego, które stanowią główną przyczynę zgonów na świecie. W strukturze zgonów z przyczyn sercowo-naczyniowych dominują rozpoznania niewydolności serca, nadciśnienia tętniczego i chorób układu naczyniowo-mózgowego. W artykule omówiono aktualną pozycję kandesartanu w leczeniu ww. jednostek chorobowych ze szczególnym zaakcentowaniem jego zastosowania u kobiet, a także właściwości przeciwzapalne molekuły, które w przyszłości mogą się przyczynić do rozszerzenia docelowej grupy pacjentów leczonych kandesartanem.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Januszkiewicz, Łukasz, & Grabowski, M. (2017). Pozahipotensyjne korzyści ze stosowania kandesartanu ze szczególnym uwzględnieniem populacji kobiet . Medycyna Faktów , 10(2(35), 93-98. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2148
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Mozaffarian D., Benjamin E.J., Go A.S. et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics – 2015 update: a report from the American Heart Association. Circulation 2015; 131: e29-322.
2. Chou A.F., Scholle S.H., Weisman C.S. et al.: Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007; 17: 120-130.
3. Gu Q., Burt V.L., Paulose-Ram R., Dillon C.F.: Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 2008; 21: 789-798.
4. Huxley R., Barzi F., Woodward M.: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
5. Huxley R.R., Woodward M.: Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-1305.
6. Kearney P.M., Whelton M., Reynolds K. et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
7. Kitler M.E.: Differences in man and women in coronary artery disease, systemic hypertension and their treatment. Am. J. Cardiol. 1992; 70: 1077-1080.
8. Kim J.K., Alley D., Seeman T. et al.: Recent changes in cardiovascular risk factors among women and men. J. Womenís Health (Larchmont) 2006; 15: 734-746.
9. Wassertheil-Smoller S.: Stroke in women. Nutr. Metab. Cardiovasc. Dis. 2010; 20(6): 419-425.
10. Timaru-Kast R., Wyschkon S., Luh C. et al.: Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 2012; 40: 935-944.
11. Sever P., Michel J., Voet B.: Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 1998; 11(4 Pt 2): 79A.
12. Elmfeldt D., Olofsson B., Meredith P.: The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002; 11(5): 293-301.
13. Himmelmann A., Keinanen-Kiukaanniemi S., Wester A. et al.: The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients w ith mild to moderate hypertension. Blood Press. 2001; 10(1): 43-51.
14. Julius S., Nesbitt S.D., Egan B.M. et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006; 354: 1685-1697.
15. Bell T.P., DeQuattro V., Lasseter K.C. et al.: Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Am. J. Cardiol. 1999; 83(2): 272-275, A6.
16. Lithell P., Hansson L., Skoog I. et al.; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21(5): 875-886.
17. Schrader J., Luders S., Kuschewski A. et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34(7): 1699-1703.
18. Tsukuda K., Mogi M., Iwanami J. et al.: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
19. Li N.C., Lee A., Whitmer R.A. et al.: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
20. Candesartan's Effects on Alzheimer's Disease And Related Biomarkers (CEDAR) [online].
21. CAndesartan vs LIsinopril Effects on the BRain (CALIBREX) [online].
22. Tronvik E., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65-69.
23. Etminan M., Levine M.A., Tomlinson G., Rochon P.A.: Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 2002; 112(8): 642-646.
24. Gulati G., Heck S.L., Ree A.H. et al.: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 2016; 37(21): 1671-1680.
2. Chou A.F., Scholle S.H., Weisman C.S. et al.: Gender disparities in the quality of cardiovascular disease care in private managed care plans. Womens Health Issues 2007; 17: 120-130.
3. Gu Q., Burt V.L., Paulose-Ram R., Dillon C.F.: Gender differences in hypertension treatment, drug utilization patterns, and blood pressure control among US adults with hypertension: data from the National Health and Nutrition Examination Survey 1999-2004. Am. J. Hypertens. 2008; 21: 789-798.
4. Huxley R., Barzi F., Woodward M.: Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ 2006; 332: 73-78.
5. Huxley R.R., Woodward M.: Cigarette smoking as a risk factor for coronary heart disease in women compared with men: a systematic review and meta-analysis of prospective cohort studies. Lancet 2011; 378: 1297-1305.
6. Kearney P.M., Whelton M., Reynolds K. et al.: Global burden of hypertension: analysis of worldwide data. Lancet 2005; 365: 217-223.
7. Kitler M.E.: Differences in man and women in coronary artery disease, systemic hypertension and their treatment. Am. J. Cardiol. 1992; 70: 1077-1080.
8. Kim J.K., Alley D., Seeman T. et al.: Recent changes in cardiovascular risk factors among women and men. J. Womenís Health (Larchmont) 2006; 15: 734-746.
9. Wassertheil-Smoller S.: Stroke in women. Nutr. Metab. Cardiovasc. Dis. 2010; 20(6): 419-425.
10. Timaru-Kast R., Wyschkon S., Luh C. et al.: Delayed inhibition of angiotensin II receptor type 1 reduces secondary brain damage and improves functional recovery after experimental brain trauma. Crit. Care Med. 2012; 40: 935-944.
11. Sever P., Michel J., Voet B.: Candesartan cilexitil (CC), A meta-analysis of time-to-effect relationship. Am. J. Hypertens. 1998; 11(4 Pt 2): 79A.
12. Elmfeldt D., Olofsson B., Meredith P.: The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy. Blood Press. 2002; 11(5): 293-301.
13. Himmelmann A., Keinanen-Kiukaanniemi S., Wester A. et al.: The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients w ith mild to moderate hypertension. Blood Press. 2001; 10(1): 43-51.
14. Julius S., Nesbitt S.D., Egan B.M. et al.: Feasibility of treating prehypertension with an angiotensin-receptor blocker. N. Engl. J. Med. 2006; 354: 1685-1697.
15. Bell T.P., DeQuattro V., Lasseter K.C. et al.: Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators. Am. J. Cardiol. 1999; 83(2): 272-275, A6.
16. Lithell P., Hansson L., Skoog I. et al.; SCOPE Study Group: The Study on Cognition and Prognosis in the Elderly (SCOPE), principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21(5): 875-886.
17. Schrader J., Luders S., Kuschewski A. et al.; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group: The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34(7): 1699-1703.
18. Tsukuda K., Mogi M., Iwanami J. et al.: Cognitive deficit in amyloid-β-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-γ activation. Hypertension 2009; 54: 782-787.
19. Li N.C., Lee A., Whitmer R.A. et al.: Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
20. Candesartan's Effects on Alzheimer's Disease And Related Biomarkers (CEDAR) [online].
21. CAndesartan vs LIsinopril Effects on the BRain (CALIBREX) [online].
22. Tronvik E., Stovner L.J., Helde G. et al.: Prophylactic treatment of migraine with an angiotensin II receptor blocker. JAMA 2003; 289: 65-69.
23. Etminan M., Levine M.A., Tomlinson G., Rochon P.A.: Efficacy of angiotensin II receptor antagonists in preventing headache: a systematic overview and meta-analysis. Am. J. Med. 2002; 112(8): 642-646.
24. Gulati G., Heck S.L., Ree A.H. et al.: Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 × 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur. Heart J. 2016; 37(21): 1671-1680.